



17W

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/815,342
	Filing Date	April 1, 2004
	First Named Inventor	ABDUL-AHAD et al.
	Art Unit	Not Known
	Examiner Name	Not Known
Total Number of Pages in This Submission	Attorney Docket Number	53208AUSM1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1449 Form with References Return Postcard
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Anna Gil, Reg. No. 46,726	
Signature		
Date	June 29, 2005	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Carole J. Smith	
Signature		Date June 30, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Continuation-in-part re application of : Group Art Unit: Not Known
Application No.: 10/815,342 : Examiner: Not Known
Filed: April 1, 2004 : Docket No. 53208AUSM1

For: Higher Doses of Interferon-Beta for Treatment of Multiple Sclerosis


Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references cited on the attached form PTO-1449 (copies enclosed) before the mailing of a first Office Action on the merits. Since this application was filed after June 30, 2003, a copy of the US Patent cited in this IDS has not been enclosed, per the waiver of the requirement under 37 CFR 1.98(a)(2)(i) published in the Official Gazette at 1276 OG 55. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method.


Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,


Anna Gil
Patent Attorney for Applicants
Reg. No. 46,726

Date: 6/24/05

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, California 94804-0099
Telephone No. 510-4758
Facsimile No. 510-262-7095
Customer No. 27586

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 53208AUSM1		APPLICATION NO. 10/815,342	
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Abdul-Ahad et al.			
				FILING DATE April 1, 2004		GROUP ART UNIT Not Yet Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	4,588,585	13May1986	Mark et al.			28SEP1984
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	2.	Knobler, R.L. et al., "Systemic Recombinant Human Interferon- β Treatment of Relapsing-Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up", <i>J. Interferon Res.</i> , (1993) 13:333-349					
	3.	Rice, G.P.A. et al., "Ibuprofen treatment versus gradual introduction of interferon β -1b in patients with MS", <i>Neurology</i> , (1999) 52:1893-1895					
	4.	McCormack, P.L. et al., "Interferon- β -1b, A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis", <i>CNS Drugs</i> , 2004:18(8) 521-546					
	5.	Cook, S.D., "Advancing treatment with interferon beta-1b (Betaferon®/Betaseron®) in the next decade. Thinking beyond the standard dose", <i>J. Neurol</i> (2003) 250(4) IV/15-IV/20					
	6.	Durelli, L. "Dose and frequency of interferon treatment matter INCOMIN and OPTIMS", <i>J. Neurol.</i> (2003) 250 (4): IV/-IV/14					
	7.	Bayas, A. et al., Lessons from 10 years of interferon beta-1b (Betaferon®/Betaseron®) treatment", <i>J. Neurol.</i> (2003) 250(4): IV/3-IV/8					
	8.	Gottesman, M.H., "Interferon beta-1b (Betaferon®/Betaferon®) is well tolerated at double the currently used dose: Inteferon dose escalation assessment of safety (IDEAS) " AAN Poster					
	9.	Gottesman, M. et al., "Results from the IDEAS (Interferon Dose Escalation Assessment and Safety) study: 500 ug dose interferon beta-1b (Betaferon®/Betaseron®) in multiple sclerosis treatment", 19 th ECTRIMS, Milan Italy 17-20 Sept 2003					
	10.	Hurwitz, B.J. et al., "Safety and tolerability of 500 μ g versus 250 μ g of interferon beta-1b (Betaferon®/ Betaseron®) – First stage of the BEYOND (Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) programme", 19 th ECTRIMS, Milan Italy 17-20 Sept 2003					
	11.	Verdun, E. et al., "Evaluation of High-Dose Interferon Beta-1B in Relapsing-Remitting MS Non-Responder Patients: The Optims Trial Safety Data", 2003 AAN Poster					
EXAMINER				DATE CONSIDERED			